<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844233</url>
  </required_header>
  <id_info>
    <org_study_id>CA1016</org_study_id>
    <nct_id>NCT00844233</nct_id>
  </id_info>
  <brief_title>Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer</brief_title>
  <acronym>PARAGON-II</acronym>
  <official_title>A Single Arm Phase II Study of Neoadjuvant Therapy Using Irinotecan Bead in Patients With Resectable Liver Metastases From Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocompatibles UK Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in the&#xD;
      neoadjuvant treatment (i.e. the Irinotecan Bead is administered prior to surgery) of&#xD;
      resectable liver metastases from colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary Endpoint of this study is Tumour resectability at surgery. Secondary Endpoints:&#xD;
&#xD;
        1. Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)&#xD;
&#xD;
        2. Tumour response assessed by imaging (RECIST and necrosis)&#xD;
&#xD;
        3. Viable residual tumour assessed by pathological evaluation of resected liver tissue.&#xD;
&#xD;
        4. Recurrence (time and site) following resection&#xD;
&#xD;
        5. Correlation of tumour response by imaging and pathology&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour resectability at surgery</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan Bead</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Irinotecan Bead</intervention_name>
    <description>Irinotecan eluting bead</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Irinotecan Bead, PARAGON Bead</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Presence of potentially resectable colorectal cancer liver metastases, with less than&#xD;
             60% liver tumour replacement. The consulting surgeon, according to local practice,&#xD;
             will determine resectability.&#xD;
&#xD;
          2. Patients having undergone complete resection of the primary tumour without gross or&#xD;
             microscopic evidence of residual disease (R0), or the primary tumour is considered R0&#xD;
             resectable at screening.&#xD;
&#xD;
          3. Age: 18-80 years.&#xD;
&#xD;
          4. ECOG Status ≤2.&#xD;
&#xD;
          5. No previous irinotecan-containing chemotherapy for advanced disease.&#xD;
&#xD;
          6. Previous chemotherapy is allowed (unless it contained irinotecan), but must have ended&#xD;
             at least one month prior to study entry.&#xD;
&#xD;
          7. Presence of adequate contraception in fertile (M/F) patients. Pregnant or lactating&#xD;
             women are excluded.&#xD;
&#xD;
          8. Absence of any other previous malignancy other than adequately treated in situ&#xD;
             carcinoma of the cervix or non-melanoma skin cancer (unless there has been a&#xD;
             disease-free interval of at least 10 years).&#xD;
&#xD;
          9. Patients should not have participated in another clinical trial with any&#xD;
             investigational drug in the 30 days prior to enrolment.&#xD;
&#xD;
         10. Absence of:&#xD;
&#xD;
               -  Peripheral neuropathy (CTC &gt; grade 1)&#xD;
&#xD;
               -  Uncontrolled congestive heart failure or angina pectoris, or hypertension or&#xD;
                  arrhythmia.&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorders&#xD;
&#xD;
               -  Active infection&#xD;
&#xD;
         11. Written informed consent according to ICH/EU GCP, and any applicable local, national&#xD;
             or international regulations.&#xD;
&#xD;
         12. Patients with liver-dominant disease, defined as ≥80% of the tumour body burden&#xD;
             confined to the liver. Unilobar disease, or bilobar disease suitable for treatment in&#xD;
             a single chemoembolisation procedure, with a maximum of 4 lesions.&#xD;
&#xD;
         13. Hematologic function: WBC ≥3.0 x 10*9/L, platelets ≥100 x 10*9/L, Absolute neutrophil&#xD;
             count &gt; 1.5 x 10*9/l.&#xD;
&#xD;
         14. Adequate organ function as measured by:&#xD;
&#xD;
               1. Serum creatinine ≤2 x upper limit of normal (ULN).&#xD;
&#xD;
               2. Serum transaminases (AST &amp; ALT) ≤5 x ULN.&#xD;
&#xD;
               3. Total bilirubin ≤1.5 x ULN.&#xD;
&#xD;
               4. Prothrombin time &gt;50% of normal.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Extrahepatic metastases constituting &gt;20% of tumour body burden.&#xD;
&#xD;
          2. Contraindications to irinotecan:&#xD;
&#xD;
               1. Chronic inflammatory bowel disease and/or bowel obstruction.&#xD;
&#xD;
               2. History of severe hypersensitivity reactions to irinotecan hydrochloride&#xD;
                  trihydrate.&#xD;
&#xD;
               3. Severe bone marrow failure.&#xD;
&#xD;
               4. Concomitant use with St John's Wort.&#xD;
&#xD;
          3. Active bacterial, viral or fungal infection within 72 hours of study entry.&#xD;
&#xD;
          4. Allergy to contrast media that cannot be managed with standard care.&#xD;
&#xD;
          5. Any contraindication for hepatic embolisation procedures:&#xD;
&#xD;
               1. porto-systemic shunt.&#xD;
&#xD;
               2. hepatofugal blood flow.&#xD;
&#xD;
               3. severe atheromatosis.&#xD;
&#xD;
          6. Contraindication to hepatic artery catheterisation, such as a patient with severe&#xD;
             peripheral vascular disease precluding catheterisation.&#xD;
&#xD;
          7. Other significant medical or surgical condition, or any medication or treatment&#xD;
             regimens, that would place the patient at undue risk, that would preclude the safe use&#xD;
             of chemoembolisation or would interfere with study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Graeme Poston, MB, MS, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant General Surgeon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna, AKH</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hépato-Biliaire, Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Aintree</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://www.biocompatibles.com</url>
    <description>Sponsor company website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 9, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

